• Valemetostat Workflow for EZH2 Lymphoma Research

  2026-09-23

  Build genotype-aware lymphoma assays around Valemetostat (DS-3201), linking EZH2 target engagement to cellular response rather than relying on viability alone. This practical workflow covers stock handling, exposure design, mutant profiling, and troubleshooting for reproducible epigenetic cancer therapy research.

• From MRSA Membranes to Immune Translation

  2026-09-22

  YZ462 illustrates how membrane disruption, cardiolipin engagement, oxidative stress, and biofilm activity can reshape anti-MRSA discovery. This thought-leadership analysis connects those findings to translational assay design and positions Recombinant Human IL-12 as a controlled immune-context variable—while separating evidence from forward-looking research strategy.

• Caffeic Acid Phenethyl Ester in NF-κB Assays

  2026-09-22

  Caffeic Acid Phenethyl Ester (CAPE) is a practical chemical probe for separating NF-κB-dependent inflammation from the Stat3-linked biology of Fyn-driven neurodegeneration. This guide connects dose-response assay design with angiogenesis, tumor-invasion, and zebrafish workflow considerations while distinguishing established evidence from proposed extensions.

• SAF312 (Libvatrep): TRPV1 Ocular Pharmacology

  2026-09-21

  The reference study builds a translational pharmacology and toxicology package for SAF312 (libvatrep), showing potent, selective, noncompetitive antagonism of human TRPV1 with ocular tissue exposure and no observed delay in post-PRK wound healing. Its integrated design clarifies how target localization, receptor pharmacology, pharmacokinetics, and multispecies safety testing can support development of a topical treatment for ocular surface pain.

• DDM for Membrane Protein Workflows

  2026-09-21

  n-Dodecyl-β-D-maltoside (DDM) combines gentle membrane solubilization with compatibility for purification, folding, functional assays, and cryo-EM sample preparation. This practical guide connects DDM handling to full-length integrin structural biology, with executable starting conditions and troubleshooting strategies.

• Hoechst 33258 for Reliable Cell Assays

  2026-09-20

  Learn how Hoechst 33258, SKU A3466, strengthens nuclear counting, live-cell imaging, and cell-cycle analysis when metabolic viability readouts are difficult to interpret. This scenario-based guide covers spectral settings, efflux-related controls, solution handling, data interpretation, and practical vendor selection.

• Adefovir (GS-0393) Research Workflow

  2026-09-19

  Build reproducible HBV antiviral and OAT1 transporter assays with Adefovir, using distinct workflows for viral DNA polymerase inhibition and renal secretion profiling. Practical preparation, exposure, structural-biology, and troubleshooting guidance helps separate compound handling problems from genuine biological effects.

• Lanabecestat (AZD3293) in BACE1 Research

  2026-09-18

  Lanabecestat (AZD3293) enables controlled BACE1 enzyme inhibition while pairing amyloid-beta measurements with functional synaptic readouts. This workflow guide translates the reference study into practical concentration design, assay controls, and troubleshooting strategies for Alzheimer's disease research.

• NET-DNA–CCDC25 Axis in Intestinal Repair

  2026-09-18

  A 2026 FASEB Journal study identifies NET-derived DNA as an inhibitor of ILC3-mediated intestinal repair in ulcerative colitis models. The work connects NET-DNA sensing through CCDC25 to reduced IL-22 production, impaired epithelial barrier restoration, and a downstream ILK–HIF-1α signaling axis.

• MK-0812 in Gut–Liver Inflammation Assays

  2026-09-17

  MK-0812 enables mechanistic testing of CCR2-dependent monocyte recruitment in gut–liver inflammation. This article shows how to use its pharmacology to distinguish intestinal trigger, circulating-cell trafficking, and hepatic inflammatory response in MASH research.

• Octyl-α-ketoglutarate: HIF-1α Assay Logic

  2026-09-17

  Explore how Octyl-α-ketoglutarate functions as a prolyl hydroxylase substrate for separating α-KG limitation from oxygen-driven HIF-1α stabilization. This article connects intracellular substrate delivery with IDH1/IDH2 and TCA cycle dysfunction research while emphasizing rigorous assay interpretation.

• Valemetostat: From EZH2 Biology to Assay Design

  2026-09-16

  Valemetostat and DS-3201 offer a precise route to interrogate EZH2-driven lymphoma biology. This article connects mutant-aware pharmacology with a cross-domain lesson from metabolic research: robust translational conclusions require layered, orthogonal assays rather than a single endpoint.

• Cisapride (R 51619) in Cardiac Electrophysiology

  2026-09-16

  Cisapride (R 51619) is a dual-action research tool for connecting 5-HT4 receptor signaling with hERG-related cardiac liabilities. Combined with iPSC-derived cardiomyocytes, high-content imaging, and orthogonal electrophysiology, it helps build practical workflows for cardiac arrhythmia research and early safety profiling.

• Separating Growth Arrest from Cell Death in Cancer

  2026-09-15

  Schwartz’s 2022 dissertation shows that relative viability and fractional viability capture different components of anticancer response: proliferative arrest and cell death. Its paired-endpoint, time-aware framework helps cancer biology researchers interpret drug screens more rigorously and avoid treating growth inhibition as a direct surrogate for killing.

• UBR1 and UBR2 in ER Stress Protein Quality Control

  2026-09-15

  The reference study identifies the N-recognins UBR1 and UBR2 as stress-responsive components of mammalian protein quality control. Its genetic, stability, and ubiquitination analyses show that these E3 ligases become more stable during ER stress and help protect cells from stress-induced apoptosis, expanding current models of ER-associated degradation.

8515 records 1/568 page Next 12345 下5页 Last page